The emergence of a new tissue economy raises issues for the governance of risk and
concepts of the body and self. This article explores the development of autologous
cell therapies as a form of tissue engineering and considers how and why autologous
applications are seen as less risky and more socially and politically acceptable. In
a careful analysis of contemporary debates around the need for new international
policies to regulate these technologies, we critically assess the discursive
strategies employed to support ideas of the body as a natural entity. Central to
these debates are assumptions that autologous applications do not threaten the moral
or corporeal integrity of the individual and that they are ‘an ethics-free
zone’. Analysis reveals that concepts such as intercorporeality need to be
refined if they are to assist our understanding of these cell-based therapies. We
consider the biopolitics of Autologous Chondrocyte Implantation (ACI) in order to
show the linkages between the culturing of cells, regulation and the reproduction of
the self.
Ashton, I., B.Ashton, P. Harrison
,
L.van Niekerk
, D. Rees,
S. Roberts
et al. (2001)
‘Autologous Chondrocyte Implantation: 1–3-year
follow-up of 20 patients treated with chondrocytes prepared in-house’
, Journal of Bone & Joint Surgery83:
344–345
.
2.
Bock, A.K.
,
D. Ibarreta
and
E. Rodriguez-Cerezo
(2003) Human Tissue-engineered Products: Today's
Market and Future Prospects – Synthesis Report EUR 21000 EN.
Institute for Prospective Technological Studies IPTS and Joint
Research Centre EC
.
3.
Brittberg, M., L.Peterson, E.Sjorgren-Jansson, T. Tallheden
and
A. Lindhal
(2003)
‘Articular Cartilage Engineering with Autologous Chondrocyte
Transplantation: A Review of Recent Developments'
, Journal of Bone & Joint Surgery(Am.)
85(A Suppl. 3):
109–115
.
4.
Brown, N.
and
A. Webster
(2004) New Medical Technologies and Society Reordering
Life.
Cambridge. Polity Press
.
5.
Brown, N., A.Faulkner, J. Kent
and
M. Michael
(in press) ‘Regulating Hybridity –
“Cleaning Up” and “Making a Mess” in the
Leaky Worlds of Xenotransplantation and Tissue Engineering’,
Social Theory and Health.
6.
Department of Health
(2001) A Code of Practice for Tissue Banks Providing Tissues
of Human Origin for Therapeutic Purposes.
London: Department of Health
.
7.
Derksen, M.H.
(2004)
‘Remaking the Body’
, unpublished paper presented at European Science Foundation
workshop on Regulation and Governance of Human Tissue Engineered Products in
Europe, held at University of West of England, June.
8.
EC (European Commission)
(2003)
Directive 2003/63/EC of 25 June 2003, amending Directive 2001/83/EC of the
Council on the Community Code Relating to Medicinal Products for Human Use
, Official Journal159 (27 June):
46–94
.
9.
EC (European Commission)
(2004)
Directive 2004/23/EC of the European Parliament and of the Council of 31
March 2004 on Setting Standards of Quality and Safety for the Donation,
Procurement, Testing, Processing, Preservation, Storage and Distribution of
Human Tissues and Cells
, Official Journal102 (7 April):
48–58
.
10.
EC (European Commission) DG Enterprise
(2004) ‘Proposal for a Harmonised Regulatory
Framework on Human Tissue Engineered Products', DG Enterprise
Consultation paper, 6 April. URL (consulted February 2006): http://pharmacos.eudra.org/F2/advtherapies/docs/Consultation_document_2004.pdf
11.
EC (European Commission) DG Enterprise
(2005) Human Tissue Engineering and Beyond: Proposal for a
Community Regulation on Advanced Therapies. Consultation Paper. May 2005.
URL (consulted February 2006): http://pharmacos.eudra.org/F2/advtherapies/docs/DraftRegulationAdvanced%20Therapies2005-May-04.pdf
12.
EC (European Commission) DG Sanco
(2004) Draft Technical Requirements for the Donation,
Procurement and Testing of Human Tissues and Cells. URL (consulted
February 2006): http://europa.eu.int/comm/health/ph_threats/human_substance/tissues_en.htm
13.
European Group on Ethics
(2004) Report on the Ethical Aspects of Human Tissue
Engineered Products. URL (consulted 29 June 2004): http://europa.eu.int/comm/european_group_ethics/docs/humantissueprod.pdf
14.
Faulkner, A.
and
J. Kent
(2001)
‘Innovation and Regulation in Human Implant Technologies:
Developing Comparative Approaches'
, Social Science and Medicine53:
895–913
.
15.
Faulkner, A., J.Kent, I.Geesink and D. FitzPatrick
(2003)
‘Human Tissue Engineered Products – Drugs or Devices?
Tackling the Regulatory Vacuum’
, British Medical Journal326:
1159–1160
.
16.
Faulkner, A., J.Kent, I. Geesink
and
D. FitzPatrick
(2004)
‘Purity and the Dangers of Innovative Therapies: Re-ordering
Regulation and Governance in the Shaping of Tissue-engineered Medical Technology’
, paper presented to EASST/4S Conference ‘Public
Proofs', École des Mines, Paris.
17.
Fox, R.
and
J. Swazey
(1992) Spare Parts, Organ Replacement in American
Society.
Oxford: Oxford University Press
.
18.
Franklin, S.
(2003) ‘Ethical Biocapital: New Strategies of
Cell Culture’, in
S. Franklin
and
M. Lock
(eds) Remaking Life and Death: Toward an Anthropology of the
Biosciences.
School of Santa Fe: American Research Press
.
19.
Franklin, S.
and
M. Lock
(eds) (2003) Remaking Life and Death: Toward an
Anthropology of the Biosciences.
Santa Fe: School of American Research Press
.
20.
Giddens, A.
(1991) Modernity and Self Identity.
Cambridge. Polity Press
.
21.
Gilman, S.
(1999) Making the Body Beautiful: A Cultural History of
Aesthetic Surgery Princeton,
NJ: Princeton University Press
.
22.
Harrison, P.
,
I. Ashton
,
W. Johnson
,
S. Turner
,
J. Richardson
and
B. Ashton
(2000)
‘The In Vitro Growth of Human Chondrocytes'
, Cell and Tissue Banking1:
255–260
.
23.
Hogle, L.
(1999) Recovering the Nation's Body: Cultural
Memory, Medicine, and the Politics of Redemption.
London: Rutgers University Press
.
24.
Hogle, L.
(2002a)
‘Jurisdictions of Authority and Expertise in Science and Medicine’
, Medical Anthropology21:
231–246
.
25.
Hogle, L.
(2002b)
‘Claims and Disclaimers: Whose Expertise Counts?’
, Medical Anthropology21:
275–306
.
26.
Hogle, L.
(2003) ‘Life/Warranty: Rechargeable
Cells', in
S. Franklin
and
M. Lock
(eds) Remaking Life and Death: Toward an Anthropology of the
Biosciences.
Santa Fe: School of American Research Press
.
27.
Hüsing, B.
,
B. Buhrlen
and
S. Gaisser
(2003) Human Tissue Engineered Products –
Today's Markets and Future Prospects. Final Report for Work Package 1:
Analysis of Actual Market Situation – Mapping of Industry and
Products.
Karlsruhe, Germany: Fraunhofer Institute for
Systems and Innovation Research
.
28.
Kent, J.
and
A. Faulkner
(2002)
‘Regulating Human Implant Technologies in Europe –
Understanding the New Regulatory Era in Medical Device Regulation’
, Health, Risk and Society4(2):
189–209
.
29.
Kent, J., A.Faulkner, I. Geesink
and
D. FitzPatrick
(2006)
‘Towards Governance of Human Tissue Engineered Technologies in
Europe: Framing the Case for a New Regulatory Regime’
, Technology Forecasting and Social Change73:
41–60
.
30.
Lindahl, A.
,
M. Brittberg
and
L. Peterson
(2003)
‘Cartilage Repair with Chondrocytes: Clinical and Cellular Aspects’
, Novartis Foundation Symposium249:
175–186
.
31.
Lock, M.
(2002) Twice Dead: Organ Transplants and the Reinvention of
Death.
Berkeley: University of California Press
.
32.
Lynch, M.
(2002)
‘Protocols, Practices, and the Reproduction of Technique in
Molecular Biology’
, British Journal of Sociology53(2):
203–220
.
33.
MDA (Medical Device Agency)
(2002) A Code of Practice for the Production of Human-derived
Therapeutic Products.
London: Department of Health
.
34.
NICE (NHS National Institute for Clinical Excellence)
(2000) Guidance on the Use of Autologous Cartilage
Transplantation for Full Thickness Cartilage Defects in Knee Joints.
Technology Appraisal Guidance No. 16. London: NICE
.
35.
Peterson, L.
(2002)
‘Technique of Autologous Chondrocyte Transplantation’
, Techniques in Knee Surgery1(1):
2–12
.
36.
Peterson, L.
et al. (2003)
‘Treatment of Osteochondritis Dissecans of the Knee with
Autologous Chondrocyte Transplantation: Results at Two to Ten Years’
, Journal of Bone & Joint Surgery(Am.) 85
(Suppl. 2):
17–24
.
37.
Rose, N.
(2001)
‘The Politics of Life Itself’
, Theory, Culture & Society18(6):
1–30
.
38.
Salter, B.
and
M. Jones
(2002)
‘Regulating Human Genetics: The Changing Politics of
Biotechnology Governance in the European Union’
, Health, Risk & Society4(3):
325–340
.
39.
Scheper-Hughes, N.
(2001)
‘Commodity Fetishism in Organ Trafficking’
, Body & Society7(2–3):
31–62
.
40.
Scheper-Hughes, N.
and
L. Wacquant
(eds) (2002) Commodifying Bodies.
London: Sage
.
41.
Sharp, L.
(2000)
‘The Commodification of the Body and its Parts’
, Annual Review of Anthropology29:
287–328
.
42.
Thacker, E.
(1999) ‘The Thickness of Tissue Engineering:
Biopolitics, Biotech and the Regenerative Body’, URL (consulted
June 2003): http://muse.jhu.edu/journals/theory_&_event/v0003/3.3thacker.html
43.
Waldby, C.
(2002a)
‘Stem Cells, Tissue Cultures and the Production of Biovalue’
, Health: An Inter disciplinary Journal for the Social Study of
Health, Illness and Medicine6(3):
305–323
.
44.
Waldby, C.
(2002b)
‘Biomedicine, Tissue Transfer and Intercorporeality’
, Feminist Theory3(3):
239–254
.
45.
Weiss, G.
(1999) Body Images: Embodiment as
Intercorporeality.
London: Routledge
.
46.
Williams, D.
(1997)
‘Engineering a Concept: The Creation of Tissue Engineering’
, Medical Device Technology10:
8–9
.
47.
WTEC
(2002) Tissue Engineering Research.
A WTEC Panel Report. Baltimore: International
Technology Research Institute, Loyola College of Maryland
.
